Director/PDMR Shareholding

RNS Number : 8380O
Kainos Group plc
11 February 2021
 

The following amendment has been made to the 'Director/PDMR Shareholdings' announcement released on 10 February 2021 at 17:00 under RNS No 6814O.

'Following this notification, Paul Gannon and his Connected Persons have a reportable shareholding of 7,329,008 ordinary shares in the issued share capital of the Company constituting 5.975% of the issued share capital of the Company.'

All other details remain unchanged.

 

The full amended text is shown below.

 

 

10 February 2021

Kainos Group plc

("Kainos" or the "Company")  

 

Director/PDMR Shareholdings

 

The Company was notified on 9 February 2021, that Paul Gannon, Director, sold 200,000 ordinary shares in the Company at an aggregated price of £13.35 per ordinary share.

The Company was further notified on 10 February 2021, that Mr Gannon transferred 50,000 ordinary shares in the Company to a Family Partnership for nil consideration.

Following this notification, Paul Gannon and his Connected Persons have a reportable shareholding of 7,329,008 ordinary shares in the issued share capital of the Company constituting 5.975% of the issued share capital of the Company.

Director / PDMR shareholdings

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a. 

Name

Paul Gannon

2. 

Reason for the notification

a. 

Position/status

Director

b. 

Initial notification

/Amendment

Initial

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. 

Name

Kainos Group plc

b. 

LEI

213800H2PQMIF3OVZY47

4.(i) 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. 

Description of the

Financial instrument/

type of instrument

Identification code

Ordinary Shares of £0.005 each

 

 

KNOS

b. 

Nature of the transaction

Sale of Shares

c. 

Price(s) and volume(s)

Price(s)

Volume(s)

£13.35

200,000

 

d. 

Aggregated information

·Aggregated volume

·Price

 

N/A

e. 

Date of the transaction

09- February-2021

f. 

Place of the transaction

LSE - Regulated Market - XLON

4.(ii) 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. 

Description of the

Financial instrument/

type of instrument

Identification code

Ordinary Shares of £0.005 each

 

 

KNOS

b. 

Nature of the transaction

Transfer of shares into a Family Partnership

c. 

Price(s) and volume(s)

Price(s)

Volume(s)

NIL

50,000

 

d. 

Aggregated information

·Aggregated volume

·Price

 

N/A

e. 

Date of the transaction

10-February-2021

f. 

Place of the transaction

LSE - Regulated Market - XLON

 

Kainos Group plc Legal Entity Identifier: 213800H2PQMIF3OVZY47 

 

Ends

 

For further information, please contact:

 

Kainos  via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Richard McCann, Chief Financial Officer

 

Investec Bank plc   +44 20 7597 5970

Patrick Robb / Ben Griffiths

 

Canaccord Genuity   +44 20 7523 4606

Simon Bridges/ Emma Gabriel

 

FTI Consulting LLP  +44 20 3727 1000

Matt Dixon / Dwight Burden / Kwaku Aning

 

About Kainos

Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms. 

 

The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. ('Workday'), responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers. 

 

The Group's Digital Platforms comprise specialised digital platforms in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.

 

Kainos has over 1,700 people across 15 offices in Europe and North America.

Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit  www.kainos.com .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKDBKNBKDKBD
UK 100

Latest directors dealings